790 related articles for article (PubMed ID: 11875496)
1. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.
Harper SQ; Hauser MA; DelloRusso C; Duan D; Crawford RW; Phelps SF; Harper HA; Robinson AS; Engelhardt JF; Brooks SV; Chamberlain JS
Nat Med; 2002 Mar; 8(3):253-61. PubMed ID: 11875496
[TBL] [Abstract][Full Text] [Related]
2. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
[TBL] [Abstract][Full Text] [Related]
3. [Adeno-associated virus vector carrying human minidystrophin gene SMCKA3999 effectively ameliorates dystrophic pathology in mdx model mice].
Li HH; Zhang SM; Fang SY; Chen CL; Luo YD; Guan Y; Wang DW; Xiao X
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1513-6. PubMed ID: 14521733
[TBL] [Abstract][Full Text] [Related]
4. Shrinking genes for therapy.
Bonetta L
Nat Med; 2002 Mar; 8(3):222. PubMed ID: 11875490
[No Abstract] [Full Text] [Related]
5. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
[TBL] [Abstract][Full Text] [Related]
6. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene.
Sakamoto M; Yuasa K; Yoshimura M; Yokota T; Ikemoto T; Suzuki M; Dickson G; Miyagoe-Suzuki Y; Takeda S
Biochem Biophys Res Commun; 2002 May; 293(4):1265-72. PubMed ID: 12054513
[TBL] [Abstract][Full Text] [Related]
7. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy.
Lai Y; Li D; Yue Y; Duan D
Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629
[TBL] [Abstract][Full Text] [Related]
8. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
[TBL] [Abstract][Full Text] [Related]
9. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
Athanasopoulos T; Foster H; Foster K; Dickson G
Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
[TBL] [Abstract][Full Text] [Related]
10. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.
Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S
Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500
[TBL] [Abstract][Full Text] [Related]
11. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
[TBL] [Abstract][Full Text] [Related]
12. Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins.
Ferrer A; Foster H; Wells KE; Dickson G; Wells DJ
Gene Ther; 2004 Jun; 11(11):884-93. PubMed ID: 14985788
[TBL] [Abstract][Full Text] [Related]
13. IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death.
Smith J; Goldsmith C; Ward A; LeDieu R
Cell Death Differ; 2000 Nov; 7(11):1109-18. PubMed ID: 11139285
[TBL] [Abstract][Full Text] [Related]
14. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
15. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
Ferrer A; Wells KE; Wells DJ
Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
[TBL] [Abstract][Full Text] [Related]
16. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
[TBL] [Abstract][Full Text] [Related]
17. The mouse dystrophin muscle promoter/enhancer drives expression of mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice.
Anderson CL; De Repentigny Y; Cifelli C; Marshall P; Renaud JM; Worton RG; Kothary R
Mol Ther; 2006 Nov; 14(5):724-34. PubMed ID: 16807118
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
19. [Current status and perspective of gene therapy on dystrophic animal model].
Takeda S
Rinsho Shinkeigaku; 2004 Nov; 44(11):911-3. PubMed ID: 15651329
[TBL] [Abstract][Full Text] [Related]
20. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
